NDRA — ENDRA Life Sciences Inc.

ENDRA Life Sciences Q2 2024 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Proceeds: Raised $7.3 million from a public offering.
• Cash Position: As of June 30, 2024, cash and cash equivalents totaled $6.4 million, expected to fund operations into the first half of 2025.
• Operating Expenses: Decreased to $2.2 million from $3 million year-over-year, primarily due to a 49% reduction in R&D expenses and a 34% decrease in sales and marketing costs. General and administrative expenses saw a slight increase of $5,000.

2. Strategic Updates and Business Highlights

• Management Changes: New CFO Richard Jacroux and Head of Regulatory and Clinical Affairs Ziad Rouag have joined the team to enhance operational effectiveness and regulatory strategy.
• Clinical Strategy: Transitioning to a hypothesis-driven, statistically powered prospective clinical trial with an expanded participant base from 20 to approximately 250 subjects.
• Market Focus: Reevaluating the go-to-market strategy for the TAEUS liver device, with a shift from hepatology as the primary target market to potentially broader segments like primary care.
• Intellectual Property: Expanded patent portfolio to 81 issued patents, enhancing protection and potential licensing opportunities.

3. Forward Guidance and Outlook

• Clinical Timeline: Aiming to complete clinical work and incorporate data into a de novo submission to the FDA by mid-2025.
• Strategic Roadmap: Plans to formalize a long-term business strategy, including exploring additional value propositions beyond the liver fat test.

4. Bad News, Challenges, or Points of Concern

• Stock Performance: The company executed a 1-for-50 reverse stock split to maintain NASDAQ listing, following a significant decline in stock price attributed to high warrant exercises from a recent public offering.
• Operational Challenges: The need to improve financial execution and operational focus amidst ongoing restructuring and strategic shifts.

5. Notable Q&A Insights

• Implementation Timeline: Management expressed confidence in executing the new strategic path within the next 9 to 12 months, focusing on clinical study completion and regulatory submission.
• FDA Submission: While no specific date was provided, the goal is to submit the FDA application by mid-2025 after completing the pivotal study.

Overall, ENDRA Life Sciences is navigating a critical phase with significant management changes and a renewed focus on clinical and regulatory strategies, while addressing financial stewardship and market positioning challenges.